Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life
M Price(Research Triangle Park Foundation), Phyllis Butow(Royal Prince Alfred Hospital), Penelope M. Webb(QIMR Berghofer Medical Research Institute), Michael Friedländer(Prince of Wales Hospital), Dirkje W. Sommeijer, Martin R. Stockler, Anna DeFazio(The University of Sydney), Melanie L. Bell(University of Colorado Health)
Cited by 56
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k